Clinical trials: Diabete Type 2
Type II; Diabetes
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
- Trial name
- AZ11040 (NCT02984644)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Diabetes Mellitus, Type 2, Substance-related Disorders
Screening, Brief Intervention, and Referral to Treatment in Primary Care
This add-on study of providing tobacco, alcohol and other drug screening, brief intervention and referral for treatment to a primary care high risk diabetic population leverages the existing research resources of a funded parent…
- Trial name
- SBIRT-PC (NCT01966432)
- Testing
- Referral to Treatment, Brief Intervention
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
- Trial name
- NCT00283049
- Testing
- Insulin Glargine, Insulin Glulisine
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
- Trial name
- SUSTAIN 7 (NCT02648204)
- Testing
- semaglutide, Dulaglutide
- Where
- 209 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,201 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes
Increasing rates of type 2 diabetes among children and adolescents has considerable long-term implications not only for the affected individuals, but also for society and the health system as a whole.
- Trial name
- NCT01814787
- Testing
- CHICA Type 2 Diabetes Module
- Where
- United States
- Volunteers
- 1,369 people
- Sponsor
- Indiana University
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT01059799)
- Testing
- insulin degludec, insulin glargine
- Where
- 53 sites in Hong Kong, Japan and 4 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.
- Trial name
- DURATION-NEO-1 (NCT01652716)
- Testing
- Exenatide once weekly suspension, Exenatide twice daily
- Where
- 58 sites in United States
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
- Trial name
- NCT01474538
- Testing
- Insulin Lispro, Insulin Aspart
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications…
- Trial name
- ELEMENT 5 (NCT02302716)
- Testing
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Where
- 44 sites in United States, India and 5 more
- Volunteers
- 493 people
- Sponsor
- Eli Lilly and Company
Motor Activity, Health Behavior
Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes
This study plans to learn more about physical activity and physical function in sedentary older adults with type 2 diabetes.
- Conditions
- Motor Activity, Health Behavior, Diabetes Mellitus, Type 2
- Trial name
- NCT02473926
- Testing
- Physical Activity, Questionnaires
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus
Impact of Medicaid Health Home on Patients With Diabetes in New York City
Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful…
- Trial name
- NCT02713321
- Where
- United States
- Volunteers
- 96,759 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetes Mellitus, Type 2
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy.
- Trial name
- NCT04090242
- Testing
- BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Becton, Dickinson and Company
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Cardiac Disease
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
We will use the target trial framework for causal inference to conduct this observational retrospective cohort study that uses claims data of adults with type 2 diabetes (T2D) included in the de-identified datasets of OptumLabs…
- Trial name
- NCT05214573
- Testing
- Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor
- Where
- United States
- Volunteers
- 386,301 people
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 2
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do…
- Trial name
- TITRATE™ (NCT00634842)
- Testing
- insulin detemir
- Where
- 69 sites in United States, Puerto Rico
- Volunteers
- 244 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
COVID-19
Impact of COVID-19 on Marshallese Communities in the U.S.
Marshallese adults in the U.S. will complete an online or telephone survey. This survey will collect data describing the impact of COVID-19 on Marshallese communities.
- Trial name
- NCT04474496
- Testing
- Assessing the impact of COVID-19
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.